Abstract: Postoperative infection following rhinoplasty is rare but can have detrimental effects on patient outcomes. Although routine use of postoperative antibiotics after rhinoplasty is a widely accepted practice, there is limited data on whether its use in preventing postsurgical complications is efficacious. This retrospective study will involve a medical record review of patients who had a rhinoplasty or septorhinoplasty surgery at UI Health between January 1, 2019 and June 1, 2020. Specifically, the review will focus on whether patients did or did not receive postoperative antibiotics after surgery and whether they had post-operative complications due to infection. This study seeks to reveal trends in antibiotic usage and infection rate after rhinoplasty. Results of the study will be recorded and shared with the medical community through presentation and/or publication.

The experimental drug therapy targets epidermal growth factor receptor (EGFR) antigens. EGFR is highly expressed in squamous cell carcinomas of the head and neck.

Objectives: The primary aim of the retrospective study is to evaluate the relationship between post-operative antibiotic use and infection rate following rhinoplasty or seporhinoplasty surgery. The research team will review medical records of patients that had either a rhinosplasty or septorhinoplasty procedure at UI Health to determine whether the patients received post-operative antibiotics and whether they had any post-operative infectious complication. If there is found to be a difference in postoperative infection rates, potential secondary endpoints include factors influencing infection rate other than antibiotic use. This includes surgical technique, sterile procedure, pre- and postoperative colonization, comorbid conditions, primary or revision nature of the surgery. Based on current existing data, we hypothesize that there will be no difference in infectious complication rates between those receiving postoperative antibiotics and those who do not receive postoperative antibiotics.